First Patient Enrolled in National Cancer Institute's Vanguard Study Evaluating Guardant Health's Shield Multi-Cancer Detection Test
Guardant's Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The Vanguard study was initiated following review and approval by the U.S. Food and Drug Administration (FDA) as part of the NCI's submission for an investigational device exemption (IDE).
'New screening technology like the Shield MCD test has the potential to detect multiple cancers earlier through a simple blood draw,' said Craig Eagle, MD, Guardant Health Global Chief Medical Officer. 'The earlier we can screen and diagnose cancers, the more options we can bring to patients and ultimately the more lives we can save. The Vanguard Study is a critical step in research to evaluate the role of this breakthrough technology in helping reduce cancer deaths.'
The Vanguard Study, conducted by the Cancer Screening Research, a new NCI-sponsored clinical trials network, is enrolling individuals ages 45-75 who do not currently have cancer and who have not received a cancer diagnosis in the past five years. All participants will be offered standard cancer screenings as part of their care. Results from the study will inform the design of a much larger randomized controlled trial to evaluate the use of MCD tests for cancer screening.
'Initiation of the Vanguard Study is an exciting milestone, as we look to evaluate a new way to screen for cancer,' said Scott Ramsey, M.D., Ph.D., director of the Hutchinson Institute for Cancer Outcomes Research at Fred Hutch Cancer Center and principal investigator for the Vanguard Study. 'The study will help us learn more about multi-cancer detection tests and assess whether they can help people from all backgrounds find cancer early, when it may be easier to treat.'
The Shield MCD test recently received Breakthrough Device Designation from the FDA for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer. The FDA grants Breakthrough Device designation to a limited set of qualifying devices that have the potential to provide more effective treatment or diagnosis of life-threatening diseases, such as cancer, than current options. The goal of the FDA's Breakthrough Devices Program is to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment and review.
For more information, please visit the Fred Hutch Cancer Center Vanguard Study website.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Palantir Stock Just Scored a Rare Upgrade Ahead of Earnings, Here's Why
Palantir Technologies (PLTR) has emerged as a standout performer in 2025, with the artificial intelligence (AI)-powered software stock soaring 97% year-to-date and leading both the S&P 500 Index ($SPX) and Nasdaq-100 Index ($IUXX). The company's remarkable momentum is primarily driven by the widespread adoption of its Artificial Intelligence Platform (AIP) across government and commercial sectors. Thanks to the stock's lights-out performance, valuation concerns have emerged as a persistent concern for PLTR. The stock trades at a forward adjusted price/earnings (P/E) ratio of 255.32 and a price-to-sales ratio of 90.0 - significantly exceeding industry norms. These elevated multiples indicate that extremely high growth expectations are already priced into Palantir shares, and the company has very little room for error going forward. Dear Nvidia Stock Fans, Mark Your Calendars for July 16 How to Buy Tesla for a 13% Discount, or Achieve a 26% Annual Return Retirement Ready: 3 Dividend Stocks to Set and Forget Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! In a note today, Mizuho analysts led by Gregg Moskowitz acknowledged Palantir's staggering valuation, even as they upgraded the AI stock to 'Neutral' from 'Underperform.' Mizuho is 'stunned by the multiple that PLTR has attained, which places its valuation dramatically above anything else in software,' according to the analysts. As a result, today's upgrade was accompanied by a relatively tepid price-target increase to $135 from $116, which represents a discount to Palantir's Tuesday closing price of $148.58. Nevertheless, MIzuho is encouraged by Palantir's 'durable' public sector pipeline and its 'growing commercial relevance,' with the analyst team arguing that PLTR 'has a legitimate chance to accelerate revenue growth for a fifth consecutive quarter' in its fiscal Q2 earnings report, due out in August. Palantir demonstrated exceptional growth in Q1 2025, with revenue increasing 39% year-over-year to $884 million, highlighted by a dramatic 71% surge in U.S. commercial revenue to $255 million. The company's government segment remains robust, with U.S. government revenue growing 45% to $373 million, while total customer count has expanded 39% year-over-year to 769 clients. Strategic developments have further strengthened Palantir's market position, including the expansion of its Maven Smart System contract with the Pentagon to over $1.3 billion through 2029. The company has also formed significant partnerships, including a collaboration with Accenture (ACN) Federal Services to deliver AI solutions to federal agencies. Looking ahead, Palantir's Q2 earnings report, scheduled for Aug. 4, is expected to show continued strength. The consensus forecast from analysts calls for earnings per share of $0.08, representing a 167% increase from the previous year. Management has forecasted full-year revenue between $3.89-3.902 billion, indicating 36% growth. Today's Mizuho upgrade is a rare bullish note for PLTR. Wall Street maintains a cautious stance with a consensus "Hold" rating - although some analysts, like Wedbush's Dan Ives, see potential for the company to become 'the next Oracle.' The key question facing investors is whether Palantir's execution and expanding AI opportunities can justify its premium valuation, or if the stock is vulnerable to a correction after its dramatic rise. While the company's long-term prospects appear promising, particularly given its strategic positioning in AI and government contracts, the current valuation levels suggest significant risks for investors. This article was generated with the support of AI and reviewed by an editor. On the date of publication, the editor did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
20 minutes ago
- Business Wire
Nalu Medical Achieves National Payer Milestone with Aetna Coverage for PNS Therapy
CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc., a leader in miniaturized neuromodulation therapies, is pleased to announce that Aetna Inc. has issued an updated medical policy designating the Nalu Neurostimulation System as medically necessary for the treatment of chronic pain of peripheral nerve origin. This change, effective July 31, 2025, marks a critical milestone in Nalu's mission to expand access to safe, innovative, drug-free alternatives for chronic pain relief. This policy shift moves Nalu from its prior classification of 'Investigational/Experimental' to 'Medically Necessary' for eligible patients—opening access to more than 22 million additional covered lives across the U.S. 'Aetna's recognition of Nalu as a medically necessary therapy is a powerful validation of our technology, clinical evidence, and commitment to patient outcomes,' said Tom West, Chief Executive Officer of Nalu Medical. 'We've built a robust body of clinical data demonstrating that Nalu PNS provides safe, effective, and durable relief for patients living with chronic, intractable pain, as well as healthcare economic data that demonstrates use of Nalu PNS results in significant cost savings. We're proud to see a leading payer like Aetna acknowledge that value, and we look forward to engaging with other health plans to expand access to this life-changing therapy.' Chronic peripheral nerve pain is often debilitating and unresponsive to conventional therapies, including long-term medication and surgery. The Nalu Neurostimulation System offers a minimally invasive, drug-free alternative that delivers precise electrical stimulation to targeted peripheral nerves, providing long-lasting relief while reducing the risks of opioid dependency and avoiding systemic side effects. About the Nalu Neurostimulation System The Nalu System consists of a fully featured, battery-free, miniaturized implantable pulse generator (IPG) 1 that is powered wirelessly by an externally worn Therapy Disc and controlled through a smartphone-based remote control app. Despite its small size, the Nalu micro-IPG™ delivers treatment capabilities similar to larger IPGs as well as advantages associated with advanced waveforms, extensive programming options, exceptional upgradability, and an expected service life of 18 years. The Nalu Neurostimulation System has been repeatedly recognized for its revolutionary technology, including being named as one of the world's top 100 new products by R&D Magazine in 2021 and ranking number 19 in the 2023 Deloitte Technology Fast 500. It is FDA-cleared for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications. To learn more, visit About Nalu Medical, Inc. Nalu is a Carlsbad, California-based medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain. The Nalu Neurostimulation System delivers gentle electrical pulses to the nervous system to modulate pain signals before they get to the brain. The Nalu Neurostimulation System was designed to address major unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians. [1] Data on file, Nalu Medical, Inc. 2025.
Business Wire
20 minutes ago
- Business Wire
ISG to Study Oil and Gas Service, Solution Providers
STAMFORD, Conn.--(BUSINESS WIRE)--Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has launched a research study examining service and solution providers that deliver AI and other digital technologies to oil and gas companies, enabling them to maintain a competitive edge and address global energy requirements. Oil and gas companies are focused on integrating digital transformation with their sustainability initiatives. This integration will help them gain substantial benefits in terms of cost reduction and operational objectives. The study results will be published in a comprehensive ISG Provider Lens ® report, called Oil and Gas Industry — Services and Solutions, scheduled to be released in January 2026. The report will cover companies offering AI tools and cloud services, enterprise asset management (EAM) services and solutions, new energy transition services and consulting and digital transformation services. Enterprise buyers will be able to use information from the report to evaluate their current vendor relationships, potential new engagements and available offerings, while ISG advisors use the information to recommend providers to the firm's buy-side clients. In response to ongoing challenges, such as supply-demand fluctuations, geopolitical uncertainty, price volatility, regulatory pressures and high tariffs, oil and gas companies are gradually accelerating digital innovation. Technology development is revolutionizing the oil and gas value chain. Enterprises are leveraging next-generation digital tools to enable predictive maintenance, real-time monitoring, process automation and informed decision-making. They are also committed to long-term investments in alternative energy projects to meet future market demands. 'Oil and gas companies are focused on integrating digital transformation with their sustainability initiatives,' said Iain Fisher, director at ISG. 'This integration will help them gain substantial benefits in terms of cost reduction and operational objectives.' ISG has distributed surveys to nearly 130 service and solution providers in the oil and gas industry. Working in collaboration with ISG's global advisors, the research team will produce four quadrants representing the services and solutions enterprises in this industry are buying, based on ISG's experience working with its clients. The four quadrants are: AI and Cloud, evaluating providers delivering AI-driven tools and cloud solutions for oil and gas enterprises. Providers are assessed on their ability to optimize business processes and partner with industry associations, regulatory bodies and technology firms. Enterprise Asset Management (EAM) Services, assessing providers offering end-to-end EAM solutions for the oil and gas industry. Providers support lifecycle asset optimization, predictive maintenance and supply chain management by leveraging digital platforms, IoT and automation to maximize asset performance and reduce operational costs. New Energy Services, covering providers of energy transition solutions that enable oil and gas companies to achieve their net zero and decarbonization goals. Providers offer digital energy transition, emission management, carbon capture and hydrogen production solutions, helping enterprises implement sustainability initiatives and comply with the evolving ESG standards. Technology, Transformation and Consulting, evaluating providers delivering digital transformation, consulting and IT modernization services for oil and gas enterprises. Providers are assessed on their ability to undertake business and operations strategy initiatives and their expertise in aligning IT operating models with evolving business requirements. A geographically focused report from the study will cover the global oil and gas market and examine products and services available in the Americas. ISG analyst Swadhin Pradhan (Americas) will serve as the author of the report. A list of identified providers and vendors and further details on the study are available in this digital brochure. Companies not listed as oil and gas service and solution providers can contact ISG and ask to be included in the study. All 2025 ISG Provider Lens ® evaluations feature expanded customer experience (CX) data that measures actual enterprise experience with specific provider services and solutions, based on ISG's continuous CX research. Enterprise customers wishing to share their experience about a specific provider or vendor are encouraged to complete this online survey. Participants will receive a copy of this report in return for their feedback. About ISG Provider Lens ® Research The ISG Provider Lens ® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
